Type 2 Inflammation Throughout Life
Educational Livestream for Healthcare Professionals April 24, 2026 17:00–18:30 CET
About the Symposium
Type 2 inflammation is a shared immunological driver across multiple specialties — from atopic dermatitis and chronic rhinosinusitis to asthma and pediatric allergic disease. This symposium brings together leading European experts to explore the latest evidence and clinical perspectives across disciplines, in one focused 90-minute session.
|
Date: Friday, April 24, 2026 |
|
Time: 17:00–18:30 CET |
|
Location: Livestream |
Who Should Attend?
This event is designed for:
- Dermatologists and allergologists
- Pulmonologists and respiratory specialists
- ENT specialists
- Pediatricians and pediatric allergologists
Programme
Time |
Session |
| 17:00 | Type 2 inflammation in the skin – Prof. Jan Gutermuth |
| 17:25 | Type 2 inflammation in the upper airways – Assoc. Prof. Marie Lundberg |
| 17:50 | Type 2 inflammation in the lower airways – Prof. Lauri Lehtimäki |
| 18:10 | Panel discussion – Chaired by PhD MD Johanna Mandelin |
| 18:20 | Q&A from the audience |
Meet the Faculty
- Prof. Jan Gutermuth – Dermatology & Allergology, UMZ Brussels, Belgium
- PhD MD Johanna Mandelin – Dermatology & Allergology, Helsinki University Hospital
- Prof. Lauri Lehtimäki – Pulmonology, Tampere University Hospital
- Assoc. Prof. Varpu Elenius – Pediatrics, Turku University Hospital
- Assoc. Prof. Marie Lundberg – ENT, Helsinki University Hospital
- PhD Anu Laulajainen – ENT, Helsinki University Hospital
Registration deadline: April 23, 2026 |
This event is addressed to healthcare professionals in dermatology, pulmonology, ENT, and pediatrics.
Sanofi står för kostnaderna gällande föredragshållare och förtäring i de fall Sanofirepresentant finns på plats. Utbildningen följer överenskommelsen om samverkansregler mellan den offentligt finansierade hälso- och sjukvården (Sveriges Kommuner och Regioner, SKR) och läkemedelsindustrin (Läkemedelsindustriföreningen, LIF). Deltagaren ansvarar för att arbetsgivarens godkännande för deltagandet är inhämtat.
MAT-FI-2600084-1.0-17/3/26
SE-FILMEN-HÄR
